RefloDx Wins Trans Atlantic Angel Grand Prize
July 10, 2025
RefloDx competed in a field of 81 companies worldwide and won the grand prize investment from the Trans Atlantic Angel Competition 7 on June 12. The diligence team scrutinized financial projections, commercialization, regulatory, and reimbursement strategies, as well as IP review, and conducted detailed interviews with advisors, clinicians, and the RefloDx management team, including Rudy Wilcox, CEO, and Greg Critchfield, MD, MS, executive chair.
BioUtah congratulates RefloDx, which also won their category in the 2025 Entrepreneur & Investor Summit pitch competition.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
